Literature DB >> 8461632

New clues to the pathophysiology of hepatorenal failure.

F Lang1, W Gerok, D Häussinger.   

Abstract

In patients with advanced liver disease, decreases in renal blood flow, glomerular filtration rate, and urinary output are frequently observed. The deterioration in renal function is usually not due to a unique cause but is the result of the concerted action of several mechanisms operating in parallel; decreased plasma protein formation and increased intrahepatic vascular resistance lead to sequestration of blood volume, favoring hypovolemia and reduction in cardiac output. At the same time enhanced formation of nitroxide leads to peripheral vasodilation; bacterial endotoxin escaping clearance by the diseased liver stimulates the expression of a long-acting nitroxide synthase. Furthermore, vasodilating intestinal mediators such as substance P escape inactivation by the liver. In the face of peripheral vasodilation the maintenance of blood pressure requires an increase in cardiac output, which is achieved by activation of sympathetic nervous tone, renal vasoconstriction, enhanced release of renin, angiotensin, aldosterone, and antidiuretic hormone, leading to renal retention of sodium and water. Renal vasoconstriction is opposed by vasodilatatory prostaglandins, and renal failure may be triggered by inhibition of prostaglandin formation. On the other hand, vasoconstrictive eicosanoids, such as thromboxane B2 and leukotriene E2, which escape hepatic inactivation, may contribute to renal vasoconstriction. Beyond these mechanisms disturbed hepatic regulation of renal function may participate in the generation of hepatorenal syndrome. The liver regulates renal function via both a hepatorenal reflex decreasing renal blood flow and a hypothetical liver-borne diuretic factor increasing renal blood flow. Both enhanced hepatorenal reflex activity and decreased formation of the liver-borne diuretic factor could participate in the pathogenesis of hepatorenal syndrome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461632     DOI: 10.1007/bf00179987

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  43 in total

1.  A simple turbidimetric time assay of the endotoxin in plasma.

Authors:  M Yokota; J Kambayashi; T Tanaka; T Tsujinaka; M Sakon; T Mori
Journal:  J Biochem Biophys Methods       Date:  1989-03

Review 2.  The hepatorenal syndrome.

Authors:  M Epstein
Journal:  Hosp Pract (Off Ed)       Date:  1989-04-15

Review 3.  Disturbed volume homeostasis in patients with cirrhosis of the liver.

Authors:  O S Better; R W Schrier
Journal:  Kidney Int       Date:  1983-02       Impact factor: 10.612

Review 4.  Renal eicosanoids as determinants of renal function in liver disease.

Authors:  M Epstein; M Lifschitz
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

5.  The treatment of the hepatorenal syndrome with intra-renal administration of prostaglandin E1.

Authors:  R M Zusman; L Axelrod; N Tolkoff-Rubin
Journal:  Prostaglandins       Date:  1977-05

6.  Effect of glucagon and glomerulopressin on the renal function of the dog.

Authors:  J Uranga; R Fuenzalida; A L Rapoport; E del Castillo
Journal:  Horm Metab Res       Date:  1979-04       Impact factor: 2.936

7.  Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease.

Authors:  R D Zipser; J C Hoefs; P F Speckart; P K Zia; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

8.  Effects of captopril on renal function in patients with cirrhosis and ascites.

Authors:  G Daskalopoulos; M Pinzani; N Murray; R Hirschberg; R D Zipser
Journal:  J Hepatol       Date:  1987-06       Impact factor: 25.083

9.  Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome.

Authors:  M Huber; S Kästner; J Schölmerich; W Gerok; D Keppler
Journal:  Eur J Clin Invest       Date:  1989-02       Impact factor: 4.686

10.  Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.

Authors:  R D Zipser; I Kronborg; W Rector; T Reynolds; G Daskalopoulos
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

View more
  2 in total

1.  Hepatosplanchnic haemodynamics and renal blood flow and function in rats with liver failure.

Authors:  P Javlé; J Yates; H G Kynaston; K F Parsons; S A Jenkins
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

2.  Impairment of natriuresis and diuresis induced by intrarenal adrenoceptor mechanisms in an experimental model of cirrhosis in rats.

Authors:  Maycon I O Milanez; Antônio M Cabral; José G P Pires; Cássia T Bergamaschi; Ruy R Campos; Henrique A Futuro Neto; Nyam F Silva
Journal:  Heliyon       Date:  2019-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.